Information Provided By: 
Fly News Breaks for April 18, 2016
PACB
Apr 18, 2016 | 11:21 EDT
Piper Jaffray analyst William Quirk lowered his Q1 estimates for Pacific Biosciences after his initial round of Sequel channel checks found six placements during the quarter compared to the 17 he modeled. Assuming Roche placed five systems, the Q1 total would come to 11, Quirk tells investors in a research note. The analyst keeps a Neutral rating on the shares with an $11 price target.
News For PACB From the Last 2 Days
There are no results for your query PACB
